Lin Shao-Lee — SEC Form 4 filings
SEC reporting owner CIK 1725092. 10 Form 4 filings on record with FilingPulse; latest filed 2026-08-14.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-01-11 to 2026-08-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 7 legs across 3 filings — 83,920 shares, $1,791,990 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: sale of 34,225 shares @ $26.99 ($923,733) in Cue Biopharma, Inc., filed 2026-08-14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | Chief Executive Officer, Director | 5 | — | 5 legs · 58,258 sh · $1,606,562 | 10 |
| ACELYRIN, Inc. (SLRN) | Chief Executive Officer, Director | 3 | — | 2 legs · 25,662 sh · $185,427 | 2 |
| Surrozen, Inc./DE (SRZN) | Director | 2 | — | — | 2 |
Form 4 filings — Lin Shao-Lee
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-14 | 4 | Cue Biopharma, Inc. (CUE) | Option exercise (M): 109,179 @ $0 · Sale (S): 34,225 @ $26.99 · Sale (S): 5,775 @ $27.75 · Sale (S): 5,423 @ $27.19 · Sale (S): 2,375 @ $28.11 · Sale (S): 10,460 @ $29.48 · +1 more | EDGAR |
| 2026-07-30 | 4/A | Cue Biopharma, Inc. (CUE) | Grant/award (A): 90,906 (derivative) @ $11 · Grant/award (A): 45,453 (derivative) | EDGAR |
| 2026-07-10 | 4 | Cue Biopharma, Inc. (CUE) | Grant/award (A): 327,537 @ $0 · Grant/award (A): 327,537 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Cue Biopharma, Inc. (CUE) | Purchase (P): 90,906 (derivative) @ $11 · Purchase (P): 45,453 (derivative) | EDGAR |
| 2026-05-07 | 4 | Cue Biopharma, Inc. (CUE) | Grant/award (A): 327,537 @ $0 · Grant/award (A): 655,074 (derivative) @ $0 | EDGAR |
| 2025-05-15 | 4 | Surrozen, Inc./DE (SRZN) | Grant/award (A): 1,333 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Surrozen, Inc./DE (SRZN) | Grant/award (A): 1,333 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | ACELYRIN, Inc. (SLRN) | Sale (S): 9,961 @ $6.63 | EDGAR |
| 2024-02-22 | 4 | ACELYRIN, Inc. (SLRN) | Sale (S): 15,701 @ $7.60 | EDGAR |
| 2024-01-11 | 4 | ACELYRIN, Inc. (SLRN) | Grant/award (A): 964,829 (derivative) @ $0 · Grant/award (A): 413,498 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-10 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1725092 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →